Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
- PMID: 40143807
- DOI: 10.1161/STROKEAHA.124.048215
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Abstract
Background: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals.
Methods: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression.
Results: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61-33.13]; P=0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04-8.91]; P=0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65-26.58]; P<0.001), and occlusive dissection (aHR, 2.34 [95% CI, 1.03-5.34]; P=0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16-0.80]; P=0.01).
Conclusions: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
Keywords: arteries; fibrinolytic agents; infarction; ischemic stroke; platelet aggregation inhibitors.
Conflict of interest statement
Dr Heldner reports grants from Swiss National Science Foundation, Swiss Heart Foundation, and SITEM Research Funds. Dr Antonenko reports grants from Swiss National Science Foundation. Dr Seiffge reports grants from AstraZeneca and compensation from AstraZeneca for consultant services. Dr Arnold reports compensation from Novo Nordisk; Covidien, Medtronic; Amgen; AstraZeneca, Bayer, Bristol Myers Squibb, Covidien, Daiichi Sankyo, Novartis, Sanofi, Pfizer; and Boehringer Ingelheim for consultant services. Dr Touzé reports employment by Caen and compensation from Elsevier for other services. Dr M. Khan reports compensation from Fred Hutchinson Cancer Research Center for end point review committee services and grants from Mayo Foundation for Medical Education and Research. Dr Rothstein reports grants from American Heart Association. Dr Rosa reports grants from Merck Sharp and Dohme Corporation. Dr Field reports compensation from Bayer for consultant services, HLS Therapeutics, AstraZeneca Canada, and Novartis for consultant services; service as Board Member for Destine Health; and compensation from Canadian Medical Protective Association for expert witness services. Dr Poppe reports compensation from Roche for other services; grants from Heart and Stroke Foundation of Canada, Foundation Brain Canada, Canadian Institutes of Health Research, and Stryker. Dr Aguiar de Sousa reports compensation from AstraZeneca, Bayer, Daiichi Sankyo, Fundação Bial, Johnson and Johnson, for other services, compensation from Organon & Co. for consultant services, compensation from University of British Columbia for Data and Safety Monitoring services. Dr Liebeskind reports compensation from Cerenovus, Genentech, Medtronic, Stryker, and Rapid Medical Ltd for consultant services. Dr Mac Grory reports grants from Duke Bass Connections, National Institutes of Health, American Heart Association, and Duke Office of Physician Scientist Development; and employment by Duke University Medical Center. Dr Kicielinski reports employment by Medical University of South Carolina and Elsevier; and compensation from Penumbra Inc for other services. Dr Siegler reports compensation from AstraZeneca for other services; employment by Cooper Hospital and University of Chicago; grants from Viz.ai; grants from Philips. Dr Sharma reports grants from the National Institutes of Health Clinical Center and a provisional patent has filed a provisional patent for a stroke etiology classifier algorithm. Dr Martins reports compensation from Boehringer Ingelheim, Penumbra Inc, Novartis, Novo Nordisk, Medtronic, Bayer, Daiichi Sankyo Company; AstraZeneca, Servier Affaires Medicales, and Pfizer for other services. Dr Sokhi reports compensation from F. Hoffmann-La Roche for other services. Dr Simpkins reports compensation from National Institute of Neurological Disorders and Stroke for data and safety monitoring services; compensation from Up to Date for other services; and grants from National Institutes of Health. Dr Stretz has received funding from Massachusetts General Hospital/BSC and Duke University Medical Center/National Institutes of Health (302000478/5K23HL161426- 02), and receives funding from the American Heart Association (24SCVNCFRE1301274). Dr Furie reports compensation from Janssen Biotech for consultant services. The other authors report no conflicts.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
